Latest news and updates from the Health Care and Social Assistance sector.
Hims & Hers stock is crashing in pre-market trading, down about 14%, after reporting a disastrous Q1 and an upbeat Q2 outlook. We don't find Q1 weakness surprising due to the Novo deal timing and tough Y/Y comparison with 1Q25. We understand that ...
The U.S.-Iran ceasefire is on "life support," according to President Trump, causing stocks to slide and crude oil to climb in the overnight hours. Kevin Green explains how the geopolitical headlines come head-to-head with the red-hot tech rally.
Shares of Hims & Hers Health (HIMS) fell sharply in premarket trading on Tuesday after the telehealth company reported weaker-than-expected first-quarter revenue and a surprise loss. The stock dropped around 15% before the opening bell after the c...
Hims and Hers Health (HIMS) is leaning harder into the booming weight loss market after raising its 2026 revenue forecast to as high as $3 billion and signaling c
Hims and Hers Health (HIMS) fell 15.61% in pre-market trading after reporting Q1 2026 revenue of $608 million, up 4% year over year but below the $617 million Wal
Digital health firm Hims & Hers' stock plummeted in premarket trading on weak first-quarter earnings. Hims reported a net loss of $92 million in the first quarter, up from $50 million last year.
Hims & Hers Health (HIMS) drops ~14% as Q1 results miss on both revenue and EPS, with US revenue down 8% year-over-year. Monthly revenue per average HIMS subscriber declined 6% YoY to $80, though total subscribers increased 9% to ~2.6M.
Shares of Hims & Hers Health fell 15% premarket on Tuesday after the telehealth company missed Wall Street estimates for first-quarter revenue and posted a surprise loss, hurt by changes in its weight-loss offerings.
Hims & Hers Health, Inc. (HIMS) Q1 2026 Earnings Call Transcript
Hims & Hers Health NYSE: HIMS reported first-quarter 2026 revenue growth and raised its full-year revenue outlook, while executives said a strategic shift in the company's weight-loss business is creating short-term margin pressure and volatility ...
It's a good day for America's largest health insurance stocks.
Shares of US health insurers surged on Tuesday morning after the Trump administration announced that Medicare Advantage payments will increase more than...
Health insurance stocks gain Medicare reprieve, SpaceX IPO roadshow coming, and more
Record Resources Inc (TSX-V:REC) announced that it has received legacy 3D seismic data from the Directorate General of Hydrocarbons under Gabon's Ministry...
Medicare Advantage payments will rise 2.5% in 2027, above estimates. That's good news for UnitedHealth, Humana and other health insurers.
The Trump administration Monday announced a 2.48% payment increase for Medicare Advantage plans for 2027, a much bigger boost than an earlier proposal that essentially kept rates flat.
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading global health and wellness platform, today announced the appointment of Kathryn Beiser as Chief Communications Officer. In this role, Beiser will lead external and ...
Hims & Hers Health, Inc. surges after securing a partnership with Novo Nordisk, resolving legal and regulatory overhangs tied to compounded GLP-1s. HIMS's long-term platform thesis centers on becoming the go-to digital health platform, leveraging ...
Hims and Hers Health has struggled, but it just inked a new partnership with Novo Nordisk.
There have been several stocks gaining investors' interest recently, including Hims and Hers Health HIMS, Sterling Infrastructure STRL, and Marvell Technology MRVL.
HIMS expands its digital care platform with new specialties, lab testing and global moves as it scales personalized telehealth services.
After falling 59% from its year-to-date (YTD) high, embattled healthcare stock Hims & Hers Health NYSE: HIMS is making headlines as shares are surging in the wake of an agreement with GLP-1 maker Novo Nordisk NYSE: NVO—the very company that filed ...
Three health-technology names are drawing fresh analyst attention this week as strategic partnerships and business pivots reframe the risk-reward calculus for each.
Hims & Hers Health (HIMS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
SAN FRANCISCO--(BUSINESS WIRE)--Hims & Hers Health, Inc. (NYSE: HIMS), the leading health and wellness platform, today announced Hims & Hers Benefits, a new way for subscribers to access the best innovations in whole body health. This new initiati...
Pre-Market Stock Futures: Futures are trading lower as many across Wall Street breathed a semi-sigh of relief yesterday after oil futures, which shot up to $120 overnight, retreated below $100 on Monday. That was the biggest spike in oil pricing s...
Shares of Hims & Hers Health (NYSE: HIMS) have staged a sharp rebound after drugmaker Novo Nordisk (NYSE: NVO) dropped its lawsuit against the company, removing what many investors considered the biggest risk.
On March 9, 2026, a new Novo Nordisk pact reshaped this telehealth player's GLP-1 strategy, margins, and legal risk profile.
Hims & Hers shares surged over 40% after renewing its partnership with Novo Nordisk to sell GLP-1 weight-loss drugs. The new deal reverses last year's public fallout, restoring a key catalyst for Hims' average revenue per subscriber. While managem...
Hims & Hers Health (HIMS) is positioned as a disruptive force in traditional healthcare, leveraging digital-first, direct-to-consumer telehealth solutions. Recent legal and regulatory overhangs have eased following a partnership with Novo Nordisk,...